Radhakrishnan P. Iyer Net Worth

The estimated Net Worth of Radhakrishnan P. Iyer is at least $137 Tysiąc dollars as of 19 November 2020. Radhakrishnan Iyer owns over 5,000 units of Spring Bank Pharmaceuticals stock worth over $136,503 and over the last 8 years Radhakrishnan sold SBPH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Radhakrishnan Iyer SBPH stock SEC Form 4 insiders trading

Radhakrishnan has made over 1 trades of the Spring Bank Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Radhakrishnan exercised 5,000 units of SBPH stock worth $6,050 on 19 November 2020.

The largest trade Radhakrishnan's ever made was exercising 5,000 units of Spring Bank Pharmaceuticals stock on 19 November 2020 worth over $6,050. On average, Radhakrishnan trades about 833 units every 0 days since 2016. As of 19 November 2020 Radhakrishnan still owns at least 112,812 units of Spring Bank Pharmaceuticals stock.

You can see the complete history of Radhakrishnan Iyer stock trades at the bottom of the page.

What's Radhakrishnan Iyer's mailing address?

Radhakrishnan's mailing address filed with the SEC is C/O SPRING BANK PHARMACEUTICALS, INC., 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON, MA, 01748.

Insiders trading at Spring Bank Pharmaceuticals

Over the last 9 years, insiders at Spring Bank Pharmaceuticals have traded over $50,400 worth of Spring Bank Pharmaceuticals stock and bought 237,689 units worth $2,510,768 . The most active insiders traders include Todd C Brady, Scott Andrew Smith oraz Kurt M Eichler. On average, Spring Bank Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $8,517. The most recent stock trade was executed by Garrett Winslow on 19 November 2020, trading 6,250 units of SBPH stock currently worth $7,563.

What does Spring Bank Pharmaceuticals do?

Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

Complete history of Radhakrishnan Iyer stock trades at Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals executives and stock owners

Spring Bank Pharmaceuticals executives and other stock owners filed with the SEC include:

• Kurt M Eichler,
  Director
• Martin J Driscoll,
  President and CEO
• David Arkowitz,
  Director
• Christiana Bardon,
  Director
• Timothy P Clackson,
  Director
• Nezam H. Afdhal,
  Chief Medical Officer
• Todd C Brady,
  Director
• Jonathan Bates,
  Director
• Scott Andrew Smith,
  Director
• Jonathan Freve,
  CFO & Treasurer
• Radhakrishnan P. Iyer,
  Chief Scientific Officer
• Garrett Winslow,
  General Counsel and Secretary
• Pamela M. Klein,
  Director
• Lori Firmani,
  VP of Finance and Treasurer